Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
Heon
Stephanie
S
Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Yeap
Beow Y
BY
Britt
Gregory J
GJ
Costa
Daniel B
DB
Rabin
Michael S
MS
Jackman
David M
DM
Johnson
Bruce E
BE
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D016543:Central Nervous System Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000401:mortality / Q000556:secondary*; D018450:Disease Progression; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D018773:Genes, erbB-1 / Q000502:physiology*; D005838:Genotype; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000502:physiology; D009367:Neoplasm Staging; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib